AMPK activation, glucose utilization, energy
Step 1 · Reconstitution
20 mg vial · Standard
1 ml BAC water
Solvent
20 mg/ml
Concentration
| Dose | Syringe draw |
|---|---|
| 5 mg | 25 U |
40 mg vial · Extended & intensive
2 ml BAC water
Solvent
20 mg/ml
Concentration
| Dose | Syringe draw |
|---|---|
| 5 mg | 25 U |
| 10 mg | 50 U |
Step 2 · Dosing schedule
Step 3 · Administration
Subcutaneously, in the morning on an empty stomach — 30–60 min before food. Ideally on training days, 1–2 hours before the workout.
MOTS-c is a mitochondrial peptide (16 amino acids) encoded by mitochondrial DNA. It activates the AMPK pathway — the cell’s main "energy sensor". It accelerates glucose utilization in muscle, improves insulin sensitivity, and stimulates beta-oxidation of fatty acids. Endogenous MOTS-c levels decline with age.
Insulin resistance and metabolic syndrome. A weight-loss plateau — when the scale stalls. Low energy, chronic fatigue. Athletes — improved endurance and glucose utilization.
Retatrutide — MOTS-c amplifies the metabolic effect (see the "Retatrutide + MOTS-c" protocol). Exercise — MOTS-c works far more effectively with training.